CAPITALSTARS
DAILY CORPORATE NEWS
Lupin jumps as Q3 earnings give positive surprise; profit, revenue beats estimate
Shares of Lupin surged 10% to Rs1803 on NSE post Q3FY2016 results which came better than expectations.
Lupin has announced the following results for the quarter ended December 31, 2015:
Standalone (YoY)
Net Profit rose by 49.31% to Rs766.42 crore Vs Rs513.30 crore.
Total Income increased by 21.45% to Rs2922.25 crore Vs Rs2406.03 crore.
Bosch announces Q3 net profit at Rs221 crore
Bosch Q3: Net Profit at Rs221 Cr Vs Rs111 Cr (YoY)
Total Income at Rs2,698 Cr Vs Rs2,381.6 Cr (YoY)
EBITDA +52.4% at Rs347.3 Cr Vs Rs228 Cr (YoY)
Eicher Motors spurts on robust Q3 consolidated net profit
Shares of Eicher Motors surged 8% to Rs18450 on NSE post Q4FY15 results led by strong performance sustains despite Chennai floods
Eicher Motors has announced the following results for the quarter ended December 31, 2015 (YoY):
Standalone (YoY)
Net Profit rose by 97.46% to Rs245.01 crore Vs Rs124.08 crore.
Total Income increased by 56.58% to Rs1304.81 crore Vs Rs833.28 crore.
Cadila rallies on better than expected Q3 consolidated net profit
Shares of Cadila Healthcare rallied 5% to Rs327 on NSE post better than expected Q3FY2016 results.
Cadila Healthcare has announced the following Q3 results for the quarter ended December 31, 2015 (YoY):
Standalone (YoY)
Net Profit rose by 30% to Rs469.50 crore Vs Rs361.20 crore.
Total Income increased by 20.36% to Rs1775.50 crore Vs Rs1475.10 crore.
Torrent Pharma gains on strong Q3 performance
Shares of Torrent Pharma gained over 2% to Rs1371.90 on NSE led by strong Q3 performance; upgrade to BUY with PT of Rs1, 741
Result Synopsis: Sales for the quarter reported growth of 33.1% to Rs 1539 crores; operating profit grew by 155.4% to Rs 613 crores; operating profit margin improved by 1698bps to 31.4% and profit for the quarter grew by 189.2% to Rs483 crore.
Strong performance driven mainly by US: For Q3FY2016, Torrent Pharmaceuticals (Torrent Pharma) results were ahead of expectation largely due to higher-than-expected revenues from its launches like gAbilify, gDetrol LA, gNexium and gNamenda in USA (up 226% YoY).
0 comments:
Post a Comment